GB201507719D0 - Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers - Google Patents

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers

Info

Publication number
GB201507719D0
GB201507719D0 GBGB1507719.1A GB201507719A GB201507719D0 GB 201507719 D0 GB201507719 D0 GB 201507719D0 GB 201507719 A GB201507719 A GB 201507719A GB 201507719 D0 GB201507719 D0 GB 201507719D0
Authority
GB
United Kingdom
Prior art keywords
peptides
scaffolds
cancers
crc
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1507719.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1507719.1A priority Critical patent/GB201507719D0/en
Publication of GB201507719D0 publication Critical patent/GB201507719D0/en
Priority to RS20210416A priority patent/RS61667B1/en
Priority to CA2984123A priority patent/CA2984123A1/en
Priority to MDE20180258T priority patent/MD3291830T2/en
Priority to ES16723966T priority patent/ES2860798T3/en
Priority to HUE16723966A priority patent/HUE053807T2/en
Priority to EA201792242A priority patent/EA201792242A1/en
Priority to CN202110645719.0A priority patent/CN113527421A/en
Priority to EP20206485.3A priority patent/EP3815712A1/en
Priority to CR20170497A priority patent/CR20170497A/en
Priority to MA053033A priority patent/MA53033A/en
Priority to US15/145,936 priority patent/US10221225B2/en
Priority to MA41393A priority patent/MA41393B2/en
Priority to LTEP16723966.4T priority patent/LT3291830T/en
Priority to MYPI2017704127A priority patent/MY185616A/en
Priority to JP2017557212A priority patent/JP6985153B2/en
Priority to SG10202013230PA priority patent/SG10202013230PA/en
Priority to KR1020177031972A priority patent/KR20170141214A/en
Priority to IL308202A priority patent/IL308202A/en
Priority to MA42045A priority patent/MA42045B1/en
Priority to SG11201708571YA priority patent/SG11201708571YA/en
Priority to PE2017002366A priority patent/PE20180487A1/en
Priority to PT167239664T priority patent/PT3291830T/en
Priority to BR112017023362-2A priority patent/BR112017023362A2/en
Priority to EP16723966.4A priority patent/EP3291830B1/en
Priority to PCT/EP2016/060007 priority patent/WO2016177784A1/en
Priority to DK16723966.4T priority patent/DK3291830T3/en
Priority to UAA201710276A priority patent/UA123941C2/en
Priority to AU2016258965A priority patent/AU2016258965B2/en
Priority to US15/145,999 priority patent/US10457712B2/en
Priority to MX2017014008A priority patent/MX2017014008A/en
Priority to US15/145,990 priority patent/US10526386B2/en
Priority to PL16723966T priority patent/PL3291830T3/en
Priority to MA43322A priority patent/MA43322A1/en
Priority to CR20230131A priority patent/CR20230131A/en
Priority to CN201680025708.XA priority patent/CN107810193B/en
Priority to SI201631142T priority patent/SI3291830T1/en
Priority to TW109141683A priority patent/TWI800770B/en
Priority to TW105114152A priority patent/TWI725026B/en
Priority to TW112111135A priority patent/TW202330590A/en
Priority to IL255126A priority patent/IL255126A0/en
Priority to CONC2017/0010830A priority patent/CO2017010830A2/en
Priority to MX2022002263A priority patent/MX2022002263A/en
Priority to PH12017501994A priority patent/PH12017501994A1/en
Priority to CL2017002766A priority patent/CL2017002766A1/en
Priority to US15/979,012 priority patent/US10435448B2/en
Priority to US15/979,089 priority patent/US10442844B2/en
Priority to US15/982,397 priority patent/US10513547B2/en
Priority to US16/556,693 priority patent/US11597752B2/en
Priority to US16/591,158 priority patent/US20200024317A1/en
Priority to AU2020244420A priority patent/AU2020244420B2/en
Priority to AU2020244418A priority patent/AU2020244418B2/en
Priority to AU2020244422A priority patent/AU2020244422B2/en
Priority to AU2020244424A priority patent/AU2020244424B2/en
Priority to AU2020244423A priority patent/AU2020244423A1/en
Priority to AU2020244419A priority patent/AU2020244419B2/en
Priority to AU2020244421A priority patent/AU2020244421B2/en
Priority to AU2020244417A priority patent/AU2020244417B2/en
Priority to HRP20210528TT priority patent/HRP20210528T1/en
Priority to JP2021059554A priority patent/JP2021112189A/en
Priority to CY20211100329T priority patent/CY1124038T1/en
Priority to US17/345,457 priority patent/US20220356220A1/en
Priority to US17/351,341 priority patent/US20210317175A1/en
Priority to US18/056,858 priority patent/US20230088845A1/en
Priority to US18/056,887 priority patent/US20230086855A1/en
Priority to US18/063,396 priority patent/US20230203113A1/en
Priority to US18/063,430 priority patent/US20230203114A1/en
Priority to US18/063,418 priority patent/US20230212244A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
GBGB1507719.1A 2015-05-06 2015-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers Ceased GB201507719D0 (en)

Priority Applications (68)

Application Number Priority Date Filing Date Title
GBGB1507719.1A GB201507719D0 (en) 2015-05-06 2015-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
RS20210416A RS61667B1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
CA2984123A CA2984123A1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
MDE20180258T MD3291830T2 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
ES16723966T ES2860798T3 (en) 2015-05-06 2016-05-04 New peptides and new peptide and carrier combinations for use in immunotherapy against colorectal carcinoma and other cancers
HUE16723966A HUE053807T2 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
EA201792242A EA201792242A1 (en) 2015-05-06 2016-05-04 NEW PEPTIDES AND COMBINATIONS OF PEPTIDES AND THEIR CARDS FOR USE IN COLORECTAL CARCINOMA AND OTHER CANCER IN IMMUNOTHERAPY
CN202110645719.0A CN113527421A (en) 2015-05-06 2016-05-04 Novel peptides and peptide compositions and scaffolds thereof for immunotherapy of colorectal cancer (CRC) and other cancers
EP20206485.3A EP3815712A1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
CR20170497A CR20170497A (en) 2015-05-06 2016-05-04 NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN IMMUNOTHERAPY AGAINST COLORRECTAL CARCINOMA AND OTHER TYPES OF CANCER
MA053033A MA53033A (en) 2015-05-06 2016-05-04 NEW PEPTIDES AND COMBINATIONS OF PEPTIDES AND SCAFFOLDING FORMED THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS
US15/145,936 US10221225B2 (en) 2015-05-06 2016-05-04 Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MA41393A MA41393B2 (en) 2015-05-06 2016-05-04 Novel peptides and combinations of peptides and scaffolds formed thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
LTEP16723966.4T LT3291830T (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
MYPI2017704127A MY185616A (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
JP2017557212A JP6985153B2 (en) 2015-05-06 2016-05-04 Novel peptides and peptides and their scaffolds for use in immunotherapy for colorectal cancer (CRC) and other cancers
SG10202013230PA SG10202013230PA (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
KR1020177031972A KR20170141214A (en) 2015-05-06 2016-05-04 Combinations of peptides and peptides and their skeletons for use in immunotherapy for colorectal carcinoma (CRC) and other cancers
IL308202A IL308202A (en) 2015-05-06 2016-05-04 Novel peptides and combination of oeptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MA42045A MA42045B1 (en) 2015-05-06 2016-05-04 Novel peptides and combinations of peptides and scaffolds formed thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
SG11201708571YA SG11201708571YA (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
PE2017002366A PE20180487A1 (en) 2015-05-06 2016-05-04 NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA AND OTHER TYPES OF CANCER
PT167239664T PT3291830T (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
BR112017023362-2A BR112017023362A2 (en) 2015-05-06 2016-05-04 peptides and combination of peptides and frameworks for use in immunotherapy against colorectal carcinoma (crc) and other cancers
EP16723966.4A EP3291830B1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
PCT/EP2016/060007 WO2016177784A1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
DK16723966.4T DK3291830T3 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma and other cancers
UAA201710276A UA123941C2 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2016258965A AU2016258965B2 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US15/145,999 US10457712B2 (en) 2015-05-06 2016-05-04 Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MX2017014008A MX2017014008A (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers.
US15/145,990 US10526386B2 (en) 2015-05-06 2016-05-04 Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
PL16723966T PL3291830T3 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
MA43322A MA43322A1 (en) 2015-05-06 2016-05-04 Novel peptides and combinations of peptides and scaffolds formed thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
CR20230131A CR20230131A (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
CN201680025708.XA CN107810193B (en) 2015-05-06 2016-05-04 Novel peptides and peptide compositions and scaffolds thereof for immunotherapy of colorectal cancer (CRC) and other cancers
SI201631142T SI3291830T1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
TW109141683A TWI800770B (en) 2015-05-06 2016-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
TW105114152A TWI725026B (en) 2015-05-06 2016-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
TW112111135A TW202330590A (en) 2015-05-06 2016-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
IL255126A IL255126A0 (en) 2015-05-06 2017-10-18 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
CONC2017/0010830A CO2017010830A2 (en) 2015-05-06 2017-10-25 Peptides and combinations of peptides and supports
MX2022002263A MX2022002263A (en) 2015-05-06 2017-10-31 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers.
PH12017501994A PH12017501994A1 (en) 2015-05-06 2017-11-02 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
CL2017002766A CL2017002766A1 (en) 2015-05-06 2017-11-02 New peptides and new combinations of peptides and supports for use in immunotherapy against colorectal carcinoma and other cancers
US15/979,012 US10435448B2 (en) 2015-05-06 2018-05-14 Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US15/979,089 US10442844B2 (en) 2015-05-06 2018-05-14 Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US15/982,397 US10513547B2 (en) 2015-05-06 2018-05-17 Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US16/556,693 US11597752B2 (en) 2015-05-06 2019-08-30 Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US16/591,158 US20200024317A1 (en) 2015-05-06 2019-10-02 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244420A AU2020244420B2 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244418A AU2020244418B2 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244422A AU2020244422B2 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244424A AU2020244424B2 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244423A AU2020244423A1 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244419A AU2020244419B2 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244421A AU2020244421B2 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
AU2020244417A AU2020244417B2 (en) 2015-05-06 2020-09-29 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
HRP20210528TT HRP20210528T1 (en) 2015-05-06 2021-03-31 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
JP2021059554A JP2021112189A (en) 2015-05-06 2021-03-31 Novel peptides and combinations of peptides and scaffolds thereof for use in immunotherapy against colorectal cancer (crc) and other cancers
CY20211100329T CY1124038T1 (en) 2015-05-06 2021-04-15 NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST CRC AND OTHER CANCER
US17/345,457 US20220356220A1 (en) 2015-05-06 2021-06-11 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
US17/351,341 US20210317175A1 (en) 2015-05-06 2021-06-18 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
US18/056,858 US20230088845A1 (en) 2015-05-06 2022-11-18 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
US18/056,887 US20230086855A1 (en) 2015-05-06 2022-11-18 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
US18/063,396 US20230203113A1 (en) 2015-05-06 2022-12-08 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
US18/063,430 US20230203114A1 (en) 2015-05-06 2022-12-08 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
US18/063,418 US20230212244A1 (en) 2015-05-06 2022-12-08 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1507719.1A GB201507719D0 (en) 2015-05-06 2015-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers

Publications (1)

Publication Number Publication Date
GB201507719D0 true GB201507719D0 (en) 2015-06-17

Family

ID=53489186

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1507719.1A Ceased GB201507719D0 (en) 2015-05-06 2015-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers

Country Status (27)

Country Link
US (9) US10526386B2 (en)
EP (2) EP3815712A1 (en)
JP (1) JP2021112189A (en)
KR (1) KR20170141214A (en)
CN (1) CN113527421A (en)
AU (9) AU2016258965B2 (en)
BR (1) BR112017023362A2 (en)
CA (1) CA2984123A1 (en)
CR (1) CR20170497A (en)
DK (1) DK3291830T3 (en)
EA (1) EA201792242A1 (en)
ES (1) ES2860798T3 (en)
GB (1) GB201507719D0 (en)
HU (1) HUE053807T2 (en)
LT (1) LT3291830T (en)
MA (4) MA53033A (en)
MD (1) MD3291830T2 (en)
MX (1) MX2017014008A (en)
PE (1) PE20180487A1 (en)
PL (1) PL3291830T3 (en)
PT (1) PT3291830T (en)
RS (1) RS61667B1 (en)
SG (2) SG10202013230PA (en)
SI (1) SI3291830T1 (en)
TW (1) TWI725026B (en)
UA (1) UA123941C2 (en)
WO (1) WO2016177784A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48487B1 (en) 2014-12-23 2021-11-30 Immatics Biotechnologies Gmbh New peptides and peptide combination for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Neoantigen identification, manufacture, and use
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
JP7075125B2 (en) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
KR101925125B1 (en) * 2016-06-16 2018-12-04 울산대학교 산학협력단 Biomarker composition for diagnosing colon cancer or prognosing metastasis of colon cancer comprising NCKAP1
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (en) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T cell receptors with improved binding
US11634486B2 (en) 2016-12-23 2023-04-25 Bluefin Biomedicine, Inc. Anti-SEZ6L2 antibodies and antibody drug conjugates
US10429364B2 (en) * 2017-01-31 2019-10-01 Thermo Finnigan Llc Detecting low level LCMS components by chromatographic reconstruction
HRP20211744T1 (en) 2017-07-14 2022-02-04 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
DE102017115966A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptide molecule with improved dual specificity
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (en) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 Reduced presentation of conjugated epitopes for new antigens
DE102017127984B4 (en) 2017-11-27 2019-12-05 Immatics US, Inc. Method for the propagation and activation of γδ T cells
MA51792A (en) 2018-02-09 2020-12-16 Immatics Us Inc T LYMPHOCYTES MANUFACTURING PROCESSES
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
PE20220164A1 (en) 2019-05-27 2022-01-28 Immatics Us Inc VIRAL VECTORS AND THEIR USE IN ADOPTIVE CELLULAR THERAPIES
BR112021024540A2 (en) 2019-06-06 2022-03-22 Immatics Biotechnologies Gmbh Methods for selecting a cell or a virus, determining the sequence of a nucleic acid, producing a cell that expresses a nucleic acid and treating a subject, selected immune cell and method for selecting an immune cell
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
MX2022010461A (en) 2020-02-24 2022-12-13 Immatics Us Inc Methods for expanding t cells for the treatment of cancer and related malignancies.
DE102020111571A1 (en) 2020-03-11 2021-09-16 Immatics US, Inc. WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES
DE102020106710A1 (en) 2020-03-11 2021-09-16 Immatics US, Inc. WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022125686A1 (en) 2020-12-08 2022-06-16 Government Of The United States Of America, As Represented By The Secretary Of Commerce Precision engineering of a cellular sense-and-response function
JP2024502034A (en) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． CD8 polypeptides, compositions, and methods of using them
US20220356252A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN114107507B (en) * 2021-09-29 2023-04-25 暨南大学 Application of ZSWIM1 protein in regulation and control of lung adenocarcinoma cell proliferation and metastasis
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
ES8105035A1 (en) 1978-12-22 1981-05-16 Biogen Nv DNA sequences.
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
FR2677653A1 (en) * 1991-06-17 1992-12-18 Inst Nat Sante Rech Med PEPTIDE FRAGMENTS FROM HUMAN CYTOCHROME P450 IID6, PEPTIDE ANTI-FRAGMENT ANTIBODIES AND THEIR APPLICATIONS IN THE DIAGNOSIS OF AUTOIMMUNE HEPATITIS.
ES2138662T3 (en) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc PRODUCTION OF ANTIBODY FRAGMENTS.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE69723230T2 (en) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL)
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6773878B1 (en) * 1999-11-09 2004-08-10 Eos Biotechnology, Inc. Methods of diagnosing of colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2001233114A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001093913A2 (en) 2000-06-05 2001-12-13 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
AU2002211665B2 (en) 2000-10-12 2005-10-20 Exelixis, Inc. Human Ect2 and methods of use
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
JP2005533486A (en) 2002-02-20 2005-11-10 ダイアックス、コープ MHC-peptide complex binding ligand
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
SE0203137D0 (en) * 2002-10-24 2002-10-24 Karolinska Innovations Ab Drug target in cancer therapy
ATE432290T1 (en) 2002-11-09 2009-06-15 Immunocore Ltd T CELL RECEPTOR ßDISPLAYß
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
EP1631682A1 (en) * 2003-06-04 2006-03-08 Agency for Science, Technology and Research Differentially regulated hepatocellular carcinoma genes and uses thereof
GB0402904D0 (en) * 2004-02-10 2004-03-17 Cyclacel Ltd Polypeptide
DE102005041616B4 (en) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanoma associated MHC class I associated oligopeptides and polynucleotides encoding them and their uses
PT1806359E (en) 2005-09-05 2010-05-25 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
CN101168566A (en) 2006-10-26 2008-04-30 北京市肿瘤防治研究所 Preparation for antibody of antineoplastic specificity marker protein TS/MEDP and use thereof
TWI438207B (en) * 2007-02-21 2014-05-21 Oncotherapy Science Inc Peptide vaccines for cancers expressing tumor-associated antigens
NZ582822A (en) 2007-07-27 2012-06-29 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
ES2536465T3 (en) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composition of tumor-associated and cancer-related peptides for the treatment of glioblastoma (GBM) and other cancers
US20120231007A1 (en) * 2009-11-23 2012-09-13 Singapore Health Services Pte. Ltd. Modulators of cell cycle progression
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TW201627003A (en) * 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 ECT2 peptides and vaccines including the same
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
BR112013010213A2 (en) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd antibodies that bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (en) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Nucleic acids encoding chimeric polypeptides for systematic library identification
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI775117B (en) 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors

Also Published As

Publication number Publication date
US20180258150A1 (en) 2018-09-13
US20180251507A1 (en) 2018-09-06
PE20180487A1 (en) 2018-03-07
EA201792242A1 (en) 2018-02-28
TW201706298A (en) 2017-02-16
SG10202013230PA (en) 2021-02-25
AU2020244423A1 (en) 2020-10-29
AU2020244418B2 (en) 2022-08-25
US20210317175A1 (en) 2021-10-14
AU2016258965B2 (en) 2020-07-02
US20200024317A1 (en) 2020-01-23
AU2020244421B2 (en) 2022-08-25
US20200002395A1 (en) 2020-01-02
CA2984123A1 (en) 2016-11-10
AU2020244420B2 (en) 2022-08-25
RS61667B1 (en) 2021-04-29
AU2020244421A1 (en) 2020-10-29
BR112017023362A2 (en) 2018-12-11
AU2020244422B2 (en) 2022-07-28
US10435448B2 (en) 2019-10-08
US10513547B2 (en) 2019-12-24
AU2020244419A1 (en) 2020-10-29
US10221225B2 (en) 2019-03-05
AU2020244422A1 (en) 2020-10-29
PL3291830T3 (en) 2021-08-02
TWI725026B (en) 2021-04-21
MD3291830T2 (en) 2021-04-30
KR20170141214A (en) 2017-12-22
AU2020244424B2 (en) 2022-08-25
MA43322A1 (en) 2019-08-30
SI3291830T1 (en) 2021-07-30
HUE053807T2 (en) 2021-07-28
MA41393B2 (en) 2021-11-30
PT3291830T (en) 2021-03-31
US11597752B2 (en) 2023-03-07
AU2020244424A1 (en) 2020-10-29
WO2016177784A1 (en) 2016-11-10
US20160339092A1 (en) 2016-11-24
US20180244741A1 (en) 2018-08-30
AU2020244418A1 (en) 2020-10-29
AU2020244417B2 (en) 2022-07-14
AU2020244417A1 (en) 2020-10-29
UA123941C2 (en) 2021-06-30
CN113527421A (en) 2021-10-22
US20160347808A1 (en) 2016-12-01
MA53033A (en) 2021-05-05
DK3291830T3 (en) 2021-04-12
SG11201708571YA (en) 2017-11-29
US10442844B2 (en) 2019-10-15
JP2021112189A (en) 2021-08-05
AU2020244419B2 (en) 2022-08-25
CR20170497A (en) 2018-02-20
AU2020244420A1 (en) 2020-10-29
MA42045B1 (en) 2021-04-30
AU2016258965A1 (en) 2017-11-30
US20160346371A1 (en) 2016-12-01
US10457712B2 (en) 2019-10-29
US10526386B2 (en) 2020-01-07
EP3291830A1 (en) 2018-03-14
EP3291830B1 (en) 2021-02-17
EP3815712A1 (en) 2021-05-05
ES2860798T3 (en) 2021-10-05
LT3291830T (en) 2021-04-26
MX2017014008A (en) 2018-08-15
MA41393A1 (en) 2018-05-31
MA42045A (en) 2018-03-14

Similar Documents

Publication Publication Date Title
SG10202013230PA (en) Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
IL289444A (en) Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
HK1244666A1 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
HK1252868A1 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201801344SA (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
HUE052820T2 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
HK1255542A1 (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
HK1255541A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL255126A0 (en) Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
HK1258386A1 (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL280734B (en) Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)